Newsletter - Welcoming 2021 with new team members and collaborations
The team at Cline Scientific hopes you had an enjoyable New Year and start to 2021! The year has already been brimming with activity and highlights for Cline.
Last week we announced that we are participating in a Horizon 2020 project VA Cure with AstraZeneca. V.A. Cure is a multi-country European MSCA-ITN network with 14 different subprojects to uncover core mechanisms of initiation and maintenance of vascular disease and leverage this information to establish novel therapeutic strategies. The network consortium consists of seven academic laboratories and two companies from across Europe and is supported by nine partner organisations. A researcher working with AstraZeneca will use Cline’s nanogradient surface and method to transform iPS stem cells into relevant cell types, which, if successful, could be a big step forward for research and developing treatments. We are excited to begin this collaboration and apply our stem cell differentiation methods on different cell types and disease areas.
In the October newsletter, we wrote about a new research manuscript that was submitted for peer review. Now, the research article titled "ToF-SIMS imaging of dual biomolecular monolayer gradients” has been accepted and is available to read in the journal Biointerphases. The research has been done in collaboration with researchers at Chalmers University of Technology and resulted in new techniques for validating the composition of our nanogradient surfaces. These results and technique are important for the precision needed for interpreting cell experiments and as a quality control tool for surface production.
You can read the publication at the following link
https://avs.scitation.org/doi/abs/10.1116/6.0000621.
StemCART
It has been an exciting time for the Cline team as we have welcomed in three new people, all focusing on the StemCART project. Dr Sven Gredevik, a specialist orthopedic surgeon, was appointed as a clinical advisor. He has extensive clinical experience to support the clinical development of our cartilage therapy StemCART. Sven will help to give guidance to Cline in bringing a regenerative medicine product into the healthcare system and to patients.
Also joining the team this month are two Master’s students from Chalmers University of Technology who will carry out their thesis project with us. Alongside our team, they will be working with the development of the StemCART product matrix. This will involve testing how different materials and techniques can be used in the therapy product to support the implanted cartilage cells and allow for the best possible joint healing and treatment.
CellRACE
Across the road, over at the cell labs at Bioventurehub at AstraZeneca, the team has been continuing the work on CellRACE, Cline’s cancer diagnostic product. Right now, the prototype is being tested, refined and is in the process of gaining patent protection.
We will continue to keep you updated, keep an eye on the website and other communication channels to follow the development. Feel free to contact us if you have questions or suggestions and do not forget to subscribe to our newsletter!
Warmest regards,
The Cline Team
Click here subscribe to future newsletters and press releases. https://news.cision.com/cline/SubscriptionRegistrationDialog
Cline Scientific AB (publ) Phone: 031-387 55 55
Argongatan 2 C Email: info@clinescientific.com
431 53 MÖLNDAL Website: www.clinescientific.com
About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase